BRAF mutation detection in hairy cell leukaemia from archival haematolymphoid specimens

Pathology

Volumn 47, Issue 4, 2015, Pages 349-354

  Thomas, Carla ^a,b   Amanuel, Benhur ^a,b   Finlayson, Jill ^a,b   Grieu Iacopetta, Fabienne ^a   Spagnolo, Dominic V ^a,b   Erber, Wendy N ^a,b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

BRAF; hairy cell leukaemia; high resolution melt curve analysis

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; FORMALDEHYDE; PARAFFIN; TUMOR MARKER;

DNA MUTATIONAL ANALYSIS; GENETICS; HAIRY CELL LEUKEMIA; HUMAN; POLYMERASE CHAIN REACTION; PROCEDURES; RETROSPECTIVE STUDY; TISSUE FIXATION;

BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FORMALDEHYDE; HUMANS; LEUKEMIA, HAIRY CELL; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; TISSUE FIXATION;

EID: 84978761964     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000245     Document Type: Article

References (32)

1. 1. Foucar, K., Falini, B., Catovsky, D., Stein, H., Hairy Cell Leukemia, 4th, 2008, World Health Organisation Press, Geneva.
2. 2. Ya-In, C., Brandwein, J., Pantalony, D., Chang, H., Hairy cell leukemia variant with features of intrasinusoidal bone marrow involvement. Arch Pathol Lab Med 129 (2005), 395–398.
3. 3. Basso, K., Liso, A., Tiacci, E., et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 199 (2004), 59–68.
4. 4. Swerdlow, S.H., Campo, E., Harris, N.L., et al. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 4th, 2008, IARC Press, Lyon.
5. 5. Tiacci, E., Trifonov, V., Schiavoni, G., et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 364 (2011), 2305–2315.
6. 6. Boyd, E.M., Bench, A.J., van ’t Veer, M.B., et al. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol 155 (2011), 609–612.
7. 7. Langabeer, S.E., O'Brien, D., Liptrot, S., et al. Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype. Int J Lab Hematol 34 (2012), 417–421.
8. 8. Langabeer, S.E., O'Brien, D., McElligott, A.M., Lavin, M., Browne, P.V., BRAF V600E-negative hairy cell leukaemia. Case Rep Hematol, 2013, 2013, 513049.
9. 9. Arcaini, L., Zibellini, S., Boveri, E., et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119 (2012), 188–191.
10. 10. Brose, M.S., Volpe, P., Feldman, M., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62 (2002), 6997–7000.
11. 11. Davies, H., Bignell, G.R., Cox, C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
12. 12. Li, W.Q., Kawakami, K., Ruszkiewicz, A., Bennett, G., Moore, J., Iacopetta, B., BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer, 5, 2006, 2.
13. 13. Maldonado, J.L., Fridlyand, J., Patel, H., et al. Determinantsof BRAF mutations in primary melanomas. J Natl Cancer Inst 95 (2003), 1878–1890.
14. 14. Elisei, R., Ugolini, C., Viola, D., et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93 (2008), 3943–3949.
15. 15. Chapman, P.B., Hauschild, A., Robert, C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
16. 16. Follows, G.A., Sims, H., Bloxham, D.M., et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 161 (2013), 150–153.
17. 17. Crisan, D., Mattson, J.C., Amplification of intermediate-size DNA sequences from formalin and B-5 fixed tissue by polymerase chain reaction. Clin Biochem 25 (1992), 99–103.
18. 18. Tiacci, E., Schiavoni, G., Forconi, F., et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF -V600E mutation. Blood 119 (2012), 192–195.
19. 19. Pollock, P.M., Harper, U.L., Hansen, K.S., et al. High frequency of BRAF mutations in nevi. Nat Genet 33 (2003), 19–20.
20. 20. Xi, L., Arons, E., Navarro, W., et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 119 (2012), 3330–3332.
21. 21. Lennerz, J.K., Klaus, B.M., Marienfeld, R.B., Moller, P., Pyrosequencing of BRAF V600E in routine samples of hairy cell leukaemia identifies CD5þ variant hairy cell leukaemia that lacks V600E. Br J Haematol 157 (2012), 267–269.
22. 22. Pardanani, A., Tefferi, A., BRAF mutations in hairy-cell leukemia. N Engl J Med, 365, 2011, 961 author reply 61-2.
23. 23. Badalian-Very, G., Vergilio, J.A., Degar, B.A., Rodriguez-Galindo, C., Rollins, B.J., Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol 156 (2012), 163–172.
24. 24. Christiansen, D.H., Andersen, M.K., Desta, F., Pedersen-Bjergaard, J., Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal trans-duction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 19 (2005), 2232–2240.
25. 25. Quesada, V., Ramsay, A.J., Rodriguez, D., Puente, X.S., Campo, E., Lopez-Otin, C., The genomic landscape of chronic lymphocytic leukemia: clinical implications. BMC Med, 11, 2013, 124.
26. 26. Chapman, M.A., Lawrence, M.S., Keats, J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471 (2011), 467–472.
27. 27. O'Donnell, E., Raje, N.S., Targeting BRAF in multiple myeloma. Cancer Discov 3 (2013), 840–842.
28. 28. Raess, P.W., Mintzer, D., Husson, M., et al. BRAF V600E is also seen in unclassifiable splenic B-cell lymphoma/leukemia, a potential mimic of hairy cell leukemia. Blood 122 (2013), 3084–3085.
29. 29. Tschernitz, S., Flossbach, L., Bonengel, M., Roth, S., Rosenwald, A., Geissinger, E., Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias. Br J Haematol 165 (2014), 529–533.
30. 30. Garnett, M.J., Marais, R., Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6 (2004), 313–319.
31. 31. Batist, G., Wu, J.H., Spatz, A., et al. Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. Front Pharmacol, 2, 2011, 59.
32. 32. Flaherty, K.T., Puzanov, I., Kim, K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363 (2010), 809–819.